Septerna FY2026 Earnings Forecast Lowered by HC Wainwright

Septerna, Inc. (NASDAQ:SEPN – Free Report) – Research analysts at HC Wainwright dropped their FY2026 earnings estimates for Septerna in a research report issued on Tuesday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.48) for the year, down from their previous estimate of ($1.15). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Septerna’s Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.37) EPS and FY2027 earnings at ($1.34) EPS.

Several other research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. Raymond James Financial reiterated a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. JonesTrading lifted their target price on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Guggenheim boosted their price target on Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Finally, Wells Fargo & Company upped their price target on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.44.

Get Our Latest Analysis on SEPN

Septerna Price Performance

Shares of Septerna stock opened at $42.60 on Thursday. The company has a market cap of $2.03 billion, a PE ratio of -33.02 and a beta of 2.20. The firm has a fifty day moving average price of $40.46 and a two-hundred day moving average price of $33.12. Septerna has a fifty-two week low of $19.69 and a fifty-two week high of $53.34.

Septerna (NASDAQ:SEPN – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The company had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. TRV GP V LLC bought a new stake in Septerna in the second quarter valued at about $208,160,143. TRV GP VI LLC acquired a new position in Septerna in the second quarter worth about $141,048,460. BlackRock Inc. acquired a new position in Septerna in the second quarter worth about $64,706,000. Jupiter Topco LLC bought a new position in Septerna during the second quarter worth about $43,723,000. Finally, Primecap Management Co. CA acquired a new stake in Septerna during the second quarter valued at approximately $39,096,000.

Insider Buying and Selling

In other Septerna news, Director Alan Ezekowitz sold 81,820 shares of Septerna stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the sale, the director owned 35,600 shares in the company, valued at $1,712,004. The trade was a 69.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Daniel Long sold 3,333 shares of Septerna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the sale, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 89,153 shares of company stock valued at $4,210,451 over the last ninety days. 5.80% of the stock is owned by company insiders.

Septerna News Roundup

Investors following SEPN have been watching these news items:

About Septerna

(Get Free Report)

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Read More

Earnings History and Estimates for Septerna (NASDAQ:SEPN)

Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.